Bengaluru: The European Commission (EC) has approved the cancer cure drug Ogivri that Biocon co-developed with its US-based partner Mylan, said the Indian biotech major Wednesday.
“The EC has granted marketing authorisation for our cancer cure drug Ogivri, developed jointly with our partner Mylan,” said the city-based firm in a statement here.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had earlier recommended approval of the drug as a biosimilar Trastuzumab to Roche’s Herceptin October 18.
The drug can be prescribed as monotherapy or in combination with other medicines depending upon the diagnosis under professional supervision.
IANS
Suggest A Correction
